rimegepant
Nurtec ODT (rimegepant) is a small-molecule CGRP receptor antagonist (a "gepant") from Pfizer. Taken as an orally disintegrating tablet, it both treats acute migraine attacks and, on an every-other-day schedule, prevents episodic migraine in adults.
This page is based on FDA prescribing information and the EMA medicine record for rimegepant, cross-checked with MedlinePlus; the mechanism is explained in plain language, and analogies are used only where they stay accurate.
How it works
Explains what the medicine does in the body, not dosing, side effects, or safety.
An analogy
During a migraine, the brain's pain system floods the surrounding nerves and blood vessels with a chemical called CGRP, like turning up the volume on a fire alarm. Rimegepant plugs the receiver so that alarm signal can't get through, turning the volume back down — whether you take it at the start of an attack or regularly to prevent one.
In simple terms
Rimegepant is a tablet that blocks the receptor for calcitonin gene-related peptide (CGRP), a small protein released during migraine attacks. CGRP causes blood vessels around the brain to widen and pain signals to intensify. By blocking the CGRP receptor, rimegepant can stop an attack that has already started and, when taken every other day, reduce the number of attacks you have. It dissolves on the tongue, so it can be taken without water — useful when migraine brings nausea.
In depth
Rimegepant is a small-molecule calcitonin gene-related peptide receptor antagonist (a gepant). It binds the CGRP receptor (CALCRL/RAMP1 complex) at a site distinct from the CGRP ligand-binding interface, competitively preventing CGRP from activating Gs-protein signaling and cAMP production in trigeminal ganglion neurons and meningeal vessels. This reduces neurogenic vasodilation, trigeminovascular activation, and peripheral and central sensitization implicated in migraine pathophysiology. Unlike monoclonal antibodies targeting the CGRP pathway, rimegepant has a short half-life suitable for both acute (as-needed) and preventive (every-other-day) dosing regimens. It is a substrate of CYP3A4 and is metabolized primarily by CYP3A4 and to a lesser extent by CYP2C9, so concomitant strong CYP3A4 inhibitors and inducers are avoided.
See it in motion
A schematic animation of the mechanism — simplified for clarity, not drawn to scale.
How rimegepant blocks the CGRP receptor
- Calcitonin gene-related peptide (CGRP) is a small protein released during migraine attacks.
- CGRP causes blood vessels around the brain to widen and pain signals to intensify.
- By blocking the CGRP receptor, rimegepant dampens the pain and inflammation cascade.
- Rimegepant can stop an attack that has already started and, when taken every other day, reduce the number of attacks.
Target: CGRP receptor (CALCRL/RAMP1)
A receptor complex on trigeminal and vascular cells that transmits CGRP signals during migraine attacks; blocking it dampens the pain and inflammation cascade.
Approved uses
Approved uses differ by country and change over time. Always follow your local prescribing information.
Approved uses in United States
FDA- Acute treatment of migraine with or without aura in adults
- Preventive treatment of episodic migraine in adults
Approved uses in European Union
EMA- Acute treatment of migraine with or without aura in adults
- Preventative treatment of episodic migraine in adults who have at least 4 migraine attacks per month
Official sources
The statements on this page trace back to these records.
- U.S. Food and Drug Administration: rimegepant prescribing information
U.S. Food and Drug Administration
- Vydura (rimegepant) — Summary of product characteristics and package leaflet, English version
European Medicines Agency
- MedlinePlus: rimegepant
MedlinePlus, U.S. National Library of Medicine
This page explains how the medicine works — it isn’t the patient leaflet. For anything that applies to you, read the leaflet that came with your medicine or ask your pharmacist.
MedUnfold provides educational content and is not medical advice. Always follow your local prescribing information and healthcare professional.